PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells-Reference-Cited by-同舟云学术

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

Published:2013-02-07 Issue:6 Volume:121 Page:962-970
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Yuki Hiromichi¹,Ueno Shikiko¹,Tatetsu Hiro¹,Niiro Hiroaki²,Iino Tadafumi²,Endo Shinya¹,Kawano Yawara¹,Komohara Yoshihiro³,Takeya Motohiro³,Hata Hiroyuki¹,Okada Seiji⁴,Watanabe Toshiki⁵,Akashi Koichi²,Mitsuya Hiroaki¹,Okuno Yutaka¹

Affiliation:

1. Department of Hematology, Kumamoto University of Medicine, Kumamoto, Japan;

2. Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan;

3. Department of Cell Pathology, Kumamoto University of Medicine, Kumamoto, Japan;

4. Division of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto, Japan; and

5. Graduate School of Frontier Sciences, University of Tokyo, Tokyo, Japan

Abstract

Key PointsPU.1 is a potent tumor suppressor in cHL cells and the induction of PU.1 is a possible therapeutic option for patients with cHL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/6/962/1368367/zh800613000962.pdf

Reference43 articles.

1. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.;Meyer;N Engl J Med,2012

2. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 Trial.;von Tresckow;J Clin Oncol,2012

3. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.;Viviani;N Engl J Med,2011

4. Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.;Chisesi;J Clin Oncol,2011

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hijacking the transcriptional activation potential of the BAF complex via Induced Proximity;2023-12-18

2. New molecular targets in Hodgkin and Reed-Sternberg cells;Frontiers in Immunology;2023-05-15

3. ANP32B suppresses B‐cell acute lymphoblastic leukemia through activation of PU.1 in mice;Cancer Science;2023-05-03

4. PU.1 negatively regulates tumorigenesis in non-small-cell lung cancer;Medical Oncology;2023-01-17

5. Comprehensive Analysis of Immune Implications and Prognostic Value of SPI1 in Gastric Cancer;Frontiers in Oncology;2022-02-14